Focused On-demand Library for STAM-binding protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O95630

UPID:

STABP_HUMAN

Alternative names:

Associated molecule with the SH3 domain of STAM; Endosome-associated ubiquitin isopeptidase

Alternative UPACC:

O95630; B5M0B6; D6W5H7; Q3MJE7

Background:

STAM-binding protein, also known as Associated molecule with the SH3 domain of STAM, plays a crucial role in cellular processes including signal transduction, BMP signaling enhancement, and regulation of cell surface receptor-mediated endocytosis. It specifically targets 'Lys-63'-linked polyubiquitin chains, distinguishing it from enzymes that cleave 'Lys-48'-linked chains. Its involvement in the negative regulation of PI3K-AKT-mTOR and RAS-MAP signaling pathways underscores its significance in cellular signaling.

Therapeutic significance:

Given its pivotal role in signal transduction and receptor-mediated endocytosis, STAM-binding protein's dysfunction is linked to Microcephaly-capillary malformation syndrome, a severe congenital disorder. Understanding the role of STAM-binding protein could open doors to potential therapeutic strategies for this and related conditions.